Original Article

You have full text access to this OnlineOpen article

Liposome-encapsulated curcumin

In vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis

  1. Lan Li M.D.,
  2. Fadi S. Braiteh M.D.,
  3. Razelle Kurzrock M.D.†,*

Article first published online: 9 AUG 2005

DOI: 10.1002/cncr.21300

Issue

Cancer

Cancer

Volume 104, Issue 6, pages 1322–1331, 15 September 2005

Additional Information

How to Cite

Li, L., Braiteh, F. S. and Kurzrock, R. (2005), Liposome-encapsulated curcumin. Cancer, 104: 1322–1331. doi: 10.1002/cncr.21300

Author Information

  1. Division of Cancer Medicine, Phase I Program and Department of Gastrointestinal Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

  1. †

    Fax: (713) 745-2374

*FACP-Unit 422, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, P.O. Box 301402, Houston, TX 77230-1402

Publication History

  1. Issue published online: 31 AUG 2005
  2. Article first published online: 9 AUG 2005
  3. Manuscript Accepted: 4 MAY 2005
  4. Manuscript Revised: 25 MAR 2005
  5. Manuscript Received: 7 MAR 2005

Funded by

  • Morton and Angela Topfer Fund for Pancreatic Cancer Research
  • SPORE in Pancreatic Cancer. Grant Number: 1 P20 CA101936-01

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (459K)

REFERENCES

  • 1
    Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin. 2002; 52: 23–47.
    Direct Link:
  • 2
    Burris HA III, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997; 15: 2403–2413.
  • 3
    Willett WC. Diet and breast cancer. J Intern Med. 2001; 249: 395–411.
    Direct Link:
  • 4
    Kelloff GJ. Perspectives on cancer chemoprevention research and drug development. Adv Cancer Res. 2000; 78: 199–334.
  • 5
    el-Bayoumy K. Evaluation of chemopreventive agents against breast cancer and proposed strategies for future clinical intervention trials. Carcinogenesis. 1994; 15: 2395–2420.
  • 6
    Ammon HP, Wahl MA. Pharmacology of Curcuma longa. Planta Med. 1991; 57: 1–7.
  • 7
    Huang M-T, Wang ZY, Georgiadis CA, Laskin JD, Conney AH. Inhibitory effects of curcumin on tumor initiation by benzo[a]pyrene and 7,12-dimethylbenz[a] anthracene. Carcinogenesis. 1992; 13: 2183–2186.
  • 8
    Conney AH, Lysz T, Ferraro T, et al. Inhibitory effect of curcumin and some related dietary compounds on tumor promotion and arachidonic acid metabolism in mouse skin. Adv Enzyme Regul 1991; 31: 385–396.
  • 9
    Lu YP, Chang RL, Lou YR, et al. Effect of curcumin on 12-O-tetradecanoylphorbol-13-acetate- and ultraviolet B light-induced expression of c-Jun and c-Fos in JB6 cells and in mouse epidermis. Carcinogenesis. 1994; 15: 2363–2370.
  • 10
    Limtrakul P, Lipigorngoson S, Namwong O, Apisariyakul A, Dunn FW. Inhibitory effect of dietary curcumin on skin carcinogenesis in mice. Cancer Lett. 1997; 116: 197–203.
  • 11
    Huang MT, Ma W, Yen P, et al. Inhibitory effects of topical application of low doses of curcumin on 12-O-tetradecanoylphorbol-13-acetate-induced tumor promotion and oxidized DNA bases in mouse epidermis. Carcinogenesis. 1997; 18: 83–88.
  • 12
    Huang MT, Lysz T, Ferraro T, Abidi TF, Laskin JD, Conney AH. Inhibitory effects of curcumin on in vitro lipoxygenase and cyclooxygenase activities in mouse epidermis. Cancer Res. 1991; 51: 813–819.
  • 13
    Huang MT, Lou YR, Xie JG, et al. Effect of dietary curcumin and dibenzoylmethane on formation of 7,12-dimethylbenz[a]anthracene-induced mammary tumors and lymphomas/leukemias in Sencar mice. Carcinogenesis 1998; 19: 1697–1700.
  • 14
    Kim JM, Araki S, Kim DJ, et al. Chemo-preventive effects of carotenoids and curcumins on mouse colon carcinogenesis after 1,2-dimethyl-hydrazine initiation. Carcinogenesis. 1998; 19: 81–85.
  • 15
    Rao CV, Rivenson A, Simi B, Reddy BS. Chemoprevention of colon carcinogenesis by dietary curcumin, a naturally occurring plant phenolic compound. Cancer Res. 1995; 55: 259–266.
  • 16
    Kawamori T, Lubet R, Steele VE, et al. Chemopreventive effect of curcumin, a naturally occurring anti-inflammatory agent, during the promotion/progression stages of colon cancer. Cancer Res. 1999; 59: 597–601.
  • 17
    Chuang SE, Kuo ML, Hsu CH, et al. Curcumin-containing diet inhibits diethylnitrosamine-induced murine hepatocarcinogenesis. Carcinogenesis. 2000; 21: 331–335.
  • 18
    Kuo ML, Huang TS, Lin JK. Curcumin, an antioxidant and anti-tumor promoter, induces apoptosis in human leukemia cells. Biochim Biophys Acta. 1996; 1317: 95–100.
  • 19
    Ranjan D, Johnston TD, Reddy KS, Wu G, Bondada S, Chen C. Enhanced apoptosis mediates inhibition of EBV-transformed lymphoblastoid cell line proliferation by curcumin. J Surg Res. 1999; 87: 1–5.
  • 20
    Piwocka K, Zablocki K, Wieckowski MR, et al. A novel apoptosis-like pathway, independent of mitochondria and caspases, induced by curcumin in human lymphoblastoid T (Jurkat) cells. Exp Cell Res. 1999; 249: 299–307.
  • 21
    Han SS, Chung ST, Robertson DA, Ranjan D, Bodada S. Curcumin causes the growth arrest and apoptosis of B cell lymphoma by downregulation of egr-1, c-myc, bcl-XL, NF-kappa B, and p53. Clin Immunol. 1999; 93: 152–161.
  • 22
    Chen H, Zhang ZS, Zhang YL, Zhou DY. Curcumin inhibits cell proliferation by interfering with the cell cycle and inducing apoptosis in colon carcinoma cells. Anticancer Res. 1999; 19: 3675–3680.
  • 23
    Mehta K, Pantazis P, McQueen T, Aggarwal BB. Curcumin (diferuloyl methane) is an antiproliferative agent against human breast tumor cell lines. Anticancer Drugs. 1997; 8: 470–481.
  • 24
    Hidaka H, Ishiko T, Furuhashi T, et al. Curcumin inhibits interleukin-8 production and enhances interleukin-8 receptor expression on the cell surface: impact on human pancreatic carcinoma cell growth by autocrine regulation. Cancer. 2000; 95: 1206–1214.
    Direct Link:
  • 25
    Korutla L, Kumar R. Inhibitory effect of curcumin on epidermal growth factor receptor kinase activity in A431 cells. Biochim Biophys Acta. 1994; 1224: 597–600.
  • 26
    Huang MT, Lou YR, Ma W, Newmark HL, Reuhl KR, Conney AH. Inhibitory effects of dietary curcumin on forestomach, duodenal and colon carcinogenesis in mice. Cancer Res. 1994; 54: 5841–5847.
  • 27
    Wang W, Abbruzzese JL, Evans DB, Larry L, Cleary KR, Chiao PJ. The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res. 1999; 5: 119–127.
  • 28
    Jobin C, Bradham CA, Russo MP, et al. Curcumin blocks cytokine-mediated NF-kappa B activation and proinflammatory gene expression by inhibiting inhibitory factor I-kappa B kinase activity. J Immunol. 1999; 163: 3474–3483.
  • 29
    Plummer SM, Holloway KA, Manson MM, et al. Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-kappaB activation via the NIK/IKK signalling complex. Oncogene. 1999; 18: 6013–6020.
  • 30
    Yip-Schneider MT, Barnard DS, Billings SD, et al. Cyxlooxygenase-2 expression in human pancreatic adenocarcinomas. Carcinogenesis. 2000; 21: 139–146.
  • 31
    Le X, Shi Q, Wang B, et al. Molecular regulation of constitutive expression of interleukin-8 in human pancreatic adenocarcinoma. J Interferon Cytokine Res. 2000; 20: 935–946.
  • 32
    Li L, Aggarwal BB, Shishodia S, Abbruzzese J, Kurzrock R. Nuclear factor-κB and IκB kinase are constitutively active in human pancreatic cells and their downregulation by curcumin (diferuloyl methane) is associated with suppression of proliferation and induction of apoptosis. Cancer. In press.
  • 33
    Moradoga L, Jaszewski R, Majumdar AN. Curcumin induced modulation of cell cycle and apoptosis in gastric and colon cancer cells. Anticancer Res. 2001; 21: 873–878.
  • 34
    Huang MT, Smart RC, Won CQ, Conney AH. Inhibitory effect of curcumin, chlorogenic acid, caffeic acid and ferulic acid on tumor promotion in mouse skin by 12-O-tetradecanoyl phorbol-13-acetate. Cancer Res. 1988; 48: 5941–5946.
  • 35
    Tanaka T, Makita H, Ohnishi M, et al. Chemoprevention of 4-nitro-quinlone 1-oxide-induced oral carcinogenesis by dietary curcumin and hesperidin: comparison with the protective effect of betacarotine. Cancer Res. 1994; 54: 4653–4659.
  • 36
    Cheng AL, Shu CH, Lin JK, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 2001; 21: 2895–2900.
  • 37
    Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-κB activity. Annu Rev Immunol. 2000; 18: 621–663.
  • 38
    Pahl HL. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene. 1999; 18: 6853–6866.
  • 39
    Williams CS, Mann M, DuBois RN. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene. 1999; 18: 7908–7916.
  • 40
    Reddy BS, Hirose Y, Lubet R, et al. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res. 2000; 15; 60: 293–297.
  • 41
    Xiong HQ, Abbruzzese JL, Lin E, Wang L, Zheng L, Xie K. NF-kappaB activity blockade impairs the angiogenic potential of human pancreatic cancer cells. Int J Cancer. 2004; 10; 108: 181–188.
    Direct Link:
  • 42
    Richmond A. NF-κB, chemokine gene transcription and tumour growth. Nat Rev Immunol. 2002; 2: 664–674.
  • 43
    Fournier DB, Gordon GB. COX-2 and colon cancer: potential targets for chemoprevention. J Cell Biochem. 2000; 77: 97–102.
    Direct Link:
  • 44
    Hida T, Yatabe Y, Achiwa H, et al. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res. 1998; 58: 3761–3764.
  • 45
    Arbiser JL, Klauber N, Rohan R, et al. Curcumin is an in vivo inhibitor of angiogenesis. Mol Med. 1998; 4: 376–383.
  • 46
    Garcea G, Jones DJ, Singh R, et al. Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration. Br J Cancer. 2004; 8; 90: 1011–1015.
View Full Article (HTML) Get PDF (459K)